

FORM PTO-1390

U.S. Department of Commerce Patent and Trademark Office

Attorney's Docket No.

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

2328-124

U.S. Application No. (if known, see 37 CFR 1.5)

09/980585

INTERNATIONAL APPLICATION NO.
PCT/FI00/00507

INTERNATIONAL FILING DATE
07 June 2000

PRIORITY DATE CLAIMED
07 June 1999

TITLE OF INVENTION: A METHOD TO ENABLE ASSESSMENT OF GROWTH AND DEATH OF MICRO-ORGANISMS


APPLICANT(S) FOR DO/EO/US: Esa-Matti LILIUS and Marko VIRTÄ

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☐ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

ITEMS 11. TO 20. below concern other document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☒ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information: Sequence Listing (10 pages); Five (5) sheets of drawings; Applicant(s) Data Sheet; Statement Pursuant to 37 CFR §1.821(f); and Statement Pursuant to 37 CFR §1.125 with marked-up copy of substitute specification.

U.S. APPLICATION NO. 097980585 <small>(37 CFR 1.50)</small>		INTERNATIONAL APPLICATION NO. PCT/F100/00507		ATTORNEY DOCKET NO. 2328-124					
21. <input checked="" type="checkbox"/> The following fees are submitted: Basic National Fee (37 CFR 1.492)(a)(1)-(5): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report Not Prepared by EPO or JPO. \$ 1,040.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report has been prepared by the EPO or JPO \$ 890.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$ 740.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but claims did not satisfy provisions of PCT Article 33(1)-(4) \$ 710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$ 100.00 <div style="text-align: right;">ENTER APPROPRIATE BASIC FEE AMOUNT =</div>				<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 50%; text-align: center;">CALCULATIONS</th> <th style="width: 50%; text-align: center;">PTO USE ONLY</th> </tr> <tr> <td style="height: 100px;"></td> <td></td> </tr> </table>		CALCULATIONS	PTO USE ONLY		
CALCULATIONS	PTO USE ONLY								
Surcharge of \$130.00 for furnishing the oath or declaration later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; text-align: center;">\$</td> <td></td> </tr> </table>		\$			
\$									
Claims	Number Filed	Number Extra	Rate						
Total Claims	10 -20 =	0	X \$18.00	\$00.00					
Independent Claims	01 - 3 =	0	X \$84.00	\$00.00					
Multiple dependent claim(s) (if applicable)			+ \$280.00	\$00.00					
TOTAL OF ABOVE CALCULATIONS =				\$1,040.00					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$520.00					
SUBTOTAL =				\$520.00					
Processing fee of \$130.00 for furnishing the English translation later than [] 20 [] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$					
TOTAL NATIONAL FEE =				\$520.00					
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$					
TOTAL FEES ENCLOSED =				\$520.00					
				Amount to be refunded	\$				
				charged	\$				
a. <input checked="" type="checkbox"/> A check in the amount of \$520.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. 02-2135 in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-2135. A duplicate copy of this sheet is enclosed. d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.									
SEND ALL CORRESPONDENCE TO: <div style="display: flex; justify-content: space-between;"> <div> Customer No. 6449 Jeffrey L. Ihnen Rothwell, Figg, Ernst & Manbeck 555 13th St., N.W. Washington, D.C. 20004 Phone: 202/783-6040 </div> <div style="text-align: right;">  Signature Jeffrey L. Ihnen Name 28.957 Registration Number </div> </div>									


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE	<i>Application Number</i>	New Application
	<i>Filing Date</i>	Herewith
	<i>First Named Inventor</i>	Esa-Matti LILIUS
	<i>Group Art Unit</i>	Unassigned
	<i>Examiner Name</i>	Unassigned
	<i>Attorney Docket No.</i>	2328-124
<i>Title of the Invention:</i> A METHOD TO ENABLE ASSESSMENT OF GROWTH AND DEATH OF MICRO-ORGANISMS		

STATEMENT PURSUANT TO 37 CFR 1.125(b)

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In the matter of the above-identified nonprovisional application, filed concurrently herewith, Applicants are submitting a substitute copy of the specification. The substitute specification contains no new matter. A marked-up version of the substitute specification, in which additions are indicated by underlining and deletions are indicated by brackets, is attached.

RESPECTFULLY SUBMITTED,					
NAME AND REG. NUMBER	Jeffrey L. Ihnen, Reg. No. 28,957				
SIGNATURE		DATE	04 December 2001		
Address	ROTHWELL, FIGG, ERNST & MANBECK, pc Suite 701-East, 555 13th Street, N.W.				
City	Washington	State	D.C.	Zip Code	20004
Country	U.S.A.	Telephone	202-783-6040	Fax	202-783-6031

<p align="center">IN THE UNITED STATES PATENT AND TRADEMARK OFFICE</p>	<i>Application Number</i>	09/980,585
	<i>Filing Date</i>	4 December 2001
	<i>First Named Inventor</i>	Esa-Matti LILIUS
	<i>Group Art Unit</i>	Unassigned
	<i>Examiner Name</i>	Unassigned
	<i>Attorney Docket No.</i>	2328-124
<p><i>Title of the Invention:</i> A METHOD TO ENABLE ASSESSMENT OF GROWTH AND DEATH OF MICRO-ORGANISMS</p>		

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Notice of Missing Requirements, response copy attached, please amend the above-identified application as follows.

IN THE SEQUENCE LISTING:

Please replace the originally filed Sequence Listing with the substitute Sequence Listing attached hereto.

REMARKS

The Sequence Listing has been revised in view of the inability of the programs to correctly number and accept a nucleic acid sequence which contains more than one coding sequence. Consequently, each sequence originally identified as "CDS" in SEQ ID NO:1 of the original Sequence Listing have been relabeled as "gene" to prevent any errors with the Checker software. The proteins encoded by these "genes" are set forth in SEQ ID Nos:2-4 as in the original Sequence Listing. The substitute Sequence Listing contains no new matter and its entry is requested.


204050 5850850

Serial No.: 09/980,585

04 March 2002

Page 2

A computer readable copy of the Sequence Listing is submitted concurrently herewith.

RESPECTFULLY SUBMITTED,			
NAME AND REG. NUMBER	Jeffrey L. Ihnen, Reg. No. 28,957		
SIGNATURE		DATE	04 March 2002

Address	ROTHWELL, FIGG, ERNST & MANBECK, pc 1425 K Street, N.W., Suite 800				
City	Washington	State	D.C.	Zip Code	20005
Country	U.S.A.	Telephone	202-783-6040	Fax	202-783-6031

Attachment: substitute Sequence Listing

09/980,585-030402

TITLE OF THE INVENTION

A METHOD TO ENABLE ASSESSMENT OF
GROWTH AND DEATH OF MICRO-ORGANISMS

5 CROSS-REFERENCE TO RELATED APPLICATION

[0001] The present application is a national stage filing under 35 U.S.C. §371 of PCT/FI00/00507 filed on 7 June 2000 and claims priority under 35 U.S.C. §119 to Finland patent application No. 991296 filed on 7 June 1999.

10 [0002] This invention relates to a method to enable the assessment of growth and death of a micro-organism within a chosen time period in an environment of interest.

BACKGROUND OF THE INVENTION

[0003] When studying growth and death of a micro-organism under the influence of specific environments, e.g. production and storage environments that e.g. could or could not be refrigerated, or involving chemicals or matrixes, e.g. antibiotics, microbial toxins, heavy metals and serum complement, microbial cultures are most often incubated for hours or days. In these circumstances death and growth occur simultaneously. If additionally some of the cells lyse, e.g. when analysing the serum complement, it is difficult to know to what one should compare the amount of living cells at the end of the experiment. Convenient methods to determine the number of living cells, e.g. by measuring luciferase bioluminescence, are known but if no more information is available it is impossible to assess to what extent growth or/and death of the micro-organisms takes or has taken place.

25 [0004] Growth rates and death rates of micro-organisms in specific environments are of interest in many areas. Death rates and growth rates of micro-organisms and especially harmful and/or pathogenic micro-organisms are of importance in risk assessments of products of the pharmaceutical industry and products for human consumption with regard to their production, storage and distribution to the consumers. Knowledge of death and growth rates of micro-organisms are of particular importance in specific applications such as in the development of
30 antibiotics, disinfectants and bactericidal products or monitoring of sterilisation, disinfection and cleaning processes.

[0005] Reporter genes coding for luminescent or/and fluorescent products have been introduced to micro-organisms to enable the assessment of the quantity or survival of living

09/980585-0304-20

micro-organisms (WO 96/23898, WO 98/14605, WO 98/30715, WO 98/36081, US 5,824,468). Even simultaneous use of luminescent and fluorescent markers has been used (Fratamico et al., Journal of Food Protection, Vol 50 No 10, 1997, 1167–1173). Luminescent and fluorescent markers have, however, only been used as markers for survival of micro-organisms and the use of two different markers within one micro-organism enabling the differentiation between growth and death rates has not been reported.

OBJECT AND SUMMARY OF THE INVENTION

[0006] The object of the present invention is to provide a method to enable the assessment of the growth and death of a micro-organism within a chosen time period in an environment of interest by introducing into said micro-organism at least two reporter genes. The method is characterised in that

- a) said reporter genes code for luminescent and/or fluorescent products and within said time period and environment at least two said products of the following are produced:
 - i) an essentially stable product produced in a, within the environment of interest, essentially known proportion to the total amount of cells of said micro-organism that are or have been alive within said chosen time period,
 - ii) a product present in said environment of interest in an essentially known proportion to the amount of cells alive at any moment within said chosen time period and
 - iii) an essentially stable product produced in a, within the environment of interest, essentially known proportion to the total amount of cells of said micro-organism that have died within said chosen time period,and said products can be measured through their luminescence and/or fluorescence;
- b) said micro-organism is incubated within the environment of interest and said luminescence and/or fluorescence is detected after said chosen time period, and
- c) the growth and death rate of the said micro-organism is assessed based on at least two of the following:

- i) the known proportion of luminescence or fluorescence to the amount of cells alive after any said chosen time period,
- ii) the known proportion of luminescence or fluorescence to the total amount of cells that are or have been alive within any said chosen time period, and
- iii) the known proportion of luminescence or fluorescence to the total amount of cells that have died within any said chosen time period.

BRIEF DESCRIPTION OF THE DRAWINGS

[0007] Figure 1 shows plasmid pGFP+luc* including genes for both GFP and firefly luciferase.

[0008] Figure 2 shows fluorescence during growth phase of *E. coli* with plasmid pGFP+luc* at 30 °C as a function of the concentration of ethanol in the cell culture.

[0009] Figure 3 shows luminescence during growth phase of *E. coli* with plasmid pGFP+luc* at 30 °C as a function of the concentration of ethanol in the cell culture.

[0010] Figure 4 shows the amount of living cells, i.e. colony forming units, according to plating during growth phase of *E. coli* with plasmid pGFP+luc* at 30 °C as a function of the concentration of ethanol in the cell culture.

[0011] Figure 5 shows the percentage of living cells according to live/dead staining and flow cytometric analysis during growth phase of *E. coli* with plasmid pGFP+luc* at 30 °C as a function of the concentration of ethanol in the cell culture.

[0012] Figure 6 shows fluorescence before and after incubation with serum complement during growth phase of *E. coli* with plasmid pGFP+luc* at 30 °C as a function of the concentration of serum complement in the cell culture.

[0013] Figure 7 shows luminescence before and after incubation with serum complement during growth phase of *E. coli* with plasmid pGFP+luc* at 30 °C as a function of the concentration of serum complement in the cell culture.

[0014] Figure 8 shows the percentage of living cells according to plating during growth phase of *E. coli* with plasmid pGFP+luc* at 30 °C as a function of the concentration of serum complement in the cell culture.

DETAILED DESCRIPTION OF THE INVENTION

[0015] The method according to the present invention can be used to assess the growth and death rate of a micro-organism within a chosen time period in any particular environment of interest. The method is applicable if two different marker genes can be introduced to the micro-organism that code for luminescent and/or fluorescent products, and the products of these fulfil at least two of the following three criteria:

a) a said luminescent product luminesces or said fluorescent product fluoresces in an essentially known proportion to the amount of cells of said micro-organism alive within said chosen time period ;

b) a said luminescent product luminesces or said fluorescent product fluoresces in an essentially known proportion to the amount of cells of said micro-organism that are or have been alive within said chosen time period, and

c) a said luminescent product luminesces or said fluorescent product fluoresces in an essentially known proportion to the amount of cells of said micro-organism that have died within said chosen time period.

[0016] In the present application the concept "micro-organism" means any micro-organism into which marker genes can be introduced so, that they will function according to the invention. "Micro-organism" can therefore stand for bacteria, yeast or fungi.

[0017] The concept of "introducing a marker gene into a micro-organism" means any method by which a marker gene can be made to function within the micro-organism according to the invention. One way of introducing marker genes into micro-organism is by constructing a recombinant strain. This can be done by transforming a strain with a plasmid including the marker genes. An alternative way to introduce reporter genes to bacteria is to utilise transposable elements. In this technique, reporter genes are inserted between insertion sequences in a delivery plasmid. The plasmid is then introduced to a cell by e.g. conjugation of transformation, and once inside the cell, genes surrounded by the insertion sequences are integrated into bacterial chromosome. Integration is stable, i.e. there is no need for a selectable marker such as antibiotic resistance.

[0018] Assessment of the growth rate and death rate of a micro-organism can be of interest in many specific environments. Within pharmaceutical research the effect of different drugs and candidates for drugs, e.g. antibiotics, on the survival of pathogenic, but also the

beneficial micro-organisms of the gut, is of interest. Thus the ultimate interest is in the behaviour of these micro-organisms in a physiological environment affected by drugs.

[0019] Another vast area where the possibility of assessing growth and death rate of specific micro-organisms is of interest is that of production, processing, storage and distribution of all products for human consumption. In this area the behaviour of pathogenic or potentially harmful micro-organisms in the different environments of the life cycle of these products is of special interest and involves many different aspects such as the influence of temperature, humidity or light and the possible use of preservatives etc.

[0020] Additionally growth and death rates of micro-organisms can be of interest for environmental evaluations e.g. when evaluating the effect of emissions into the environment.

[0021] Luminescent or fluorescent products coded by reporter genes in different embodiments of this invention can vary as long as their proportion to either the total amount of cells alive, to cells that are or have been alive, or to cells that have died is essentially known. Growth and death rate can be assessed if two of the following: cells alive, cells that are or have been alive, or cells that have died can be determined. Thus luminescence and/or fluorescence measured can be e.g. of a product which is expressed e.g. constitutively or triggered by a specific phase (e.g. replication or death) of the lifecycle of each cell, is stable or labile or which luminescence or fluorescence is dependant on a factor that relates e.g. to a specific phase of the lifecycle of each cell. Depending on the individual characteristics of said product—how produced, stable or labile, possible dependence of its luminescence or fluorescence of said factors etc.—the measured luminescence or fluorescence can be in proportion to one of the three unknown of which two must be known to be able to assess the growth rate and death rate of said cells.

[0022] According to one specific embodiment of the invention assessment of the growth and death rate of an *Esherichia coli* strain under the influence of different chemicals or matrixes was enabled by constructing a recombinant strain, which expresses both luciferase and GFP. Altogether the effect of a number of different chemicals and matrixes, such as CdCl_2 , ethanol, the antibiotics chloramphenicol, rifampicin, and tetracyclin, as well as serum complement on said recombinant *E. coli* strain was tested and found applicable.

[0023] The invention will be described in more detail by the following study in which the growth rate and death rate of a recombinant *Esherichia coli* strain, which expresses both luciferase and GFP, is assessed under the influence of ethanol or serum complement.

Summary of the study

[0024] Genes for luciferase and green fluorescent protein have recently raised interest as reporter genes. Luciferase is an enzyme that produces luminescence in the presence of substrate luciferin, molecular oxygen and ATP. Green fluorescent protein (GFP), produces green fluorescence when excited with light. Many mutated forms of GFP have been introduced: some have different excitation and emission wavelengths from the wild type and some mutants form more stable proteins at higher temperatures.

[0025] We constructed a recombinant strain of *E. coli*, which expresses both luciferase and GFP. In our construction we used a mutant of GFP, which is more stable at temperatures over +30 °C and it matures quicker than the wild type. Luciferase was from North American firefly, *Photinus pyralis*.

[0026] The *E. coli* strain MC1061 was transformed with a plasmid including genes for both GFP and firefly luciferase. Figure 1 describes the plasmid in general. The sequence of the plasmid is disclosed in the sequence listing. Essential codings of the sequence are as follows:

lac promoter	95–199
GFP	289–1008
firefly luciferase	1044–2696
β -lactamase	3251–4111

[0027] In our construct, see Figure 1, the luciferase gene is situated next to the GFP gene and both genes are transcribed in the same direction. The transcription is started at the lac promoter in front of GFP. The lac promoter is constitutively active, because the MC1061 cells lack its repressor. The plasmid also has a gene for ampicillin resistance (β -lactamase).

[0028] The transformed *E. coli* strain was propagated under the influence of different concentrations of ethanol or serum complement.

Methods

Growth conditions

[0029] One colony from a pure culture plate was inoculated in 5 ml of LB-medium with ampicillin (100 μ g/ml) and grown at +37 °C in a shaker, 250 rpm, for about three hours. After that, the number of cells per millilitre was determined with flow cytometry by using fluorescent spherical latex particles as a reference. One million cells were then removed to an erlenmeyer

with 50 ml of LB medium and ampicillin. The culture was grown over night in a shaker, 190 rpm, at room temperature to prevent the culture from growing into the stationary phase during the night. In the morning, the culture was transferred to and grown in a shaker, 330 rpm, until the stationary phase was reached or used after growth at +30 °C for about 1 h to study the influence of ethanol or serum complement as described below.

Influence of chemicals on the propagation of *E. coli*

[0030] The culture obtained as described above was used to study the influence of ethanol or serum complement as follows:

Ethanol

[0031] Ethanol (Aa, Primalco Oy) was diluted into pure water to obtain concentrations of 50, 45, 25, 10, 5, 1 and 0 % of ethanol when 500 µl of said dilution was added to 500 µl of said culture in an eppendorf tube. The mixture was vortexed and incubated for 5 minutes before measuring fluorescence and luminescence. Live cells were again counted by plating and also by live/dead staining. In the live/dead protocol used the stain *cyto 9* stains all cells whereas propidium iodide stains only the dead cells. After staining, cells are passed through a flow cytometer, with which dead and live cells can be differentiated and their proportion determined. (Virta et al. (1998) Appl. Environ. Microbiol. 64: 515–519.)

Serum complement

[0032] The influence of serum complement on the said recombinant *E. coli* strain was studied using an incubation time of 90 min as described for a different recombinant *E. coli* strain used in Virta et al. (1998) Appl. Environ. Microbiol. 64: 515–519.

Fluorescence and luminescence measurements

[0033] The measurements were done with a combined fluoro- and luminometer, Fluoroscan Ascent FL, provided by Labsystems Ltd. (Helsinki, Finland). Cell growth was simultaneously followed with a flow cytometer.

[0034] For the measurements, 100 µl of bacterial culture was pipetted into the microtiter plate wells. Fluorescence was measured using 485 nm for excitation and 510 nm for emission. Measuring time was 20 ms. After the fluorescence measurement 100 µl of luciferin in 0.1 M citric acid-sodium citrate buffer (pH 5.0) was dispensed into the wells and the plate was shaken

for two minutes (shaking diameter 1 mm, 1 020 rpm), after which luminescence was recorded with a measuring time of 1000 ms.

Plating

[0035] Samples for plating were diluted 10^2 to 10^7 fold with 150 mM NaCl and plated onto L agar plates (L broth containing 1.6 % agar). Colonies were counted after overnight incubation at 37 °C.

Live/dead staining and Flow cytometric analysis

[0036] Bacteria from 1 000 µl of cell culture were used for live/dead staining and flow cytometric analysis using a LIVE/DEAD BacLight bacterial viability kit (catalogue no. L-7005) for microscopy and quantitative analysis obtained from Molecular Probes Europe (Leiden, The Netherlands) and Fluoresbrite beads (diameter, 1.8 µm) obtained from Polysciences Inc. (Warrington, Pa.) as described in Virta et al. (1998) Appl. Environ. Microbiol. 64: 515–519.

Results

[0037] When the cultures were transferred to +30 °C, the cells grew logarithmically for 1-4 hours depending on the initial cell concentration. Luminescence and fluorescence rose logarithmically and were essentially constant per cell. Thus cell number could be assessed based on luminescence or fluorescence.

[0038] When ethanol was added in different concentrations to the growth medium (see Figures 4 and 5) death was, after a very short incubation period of 5 min, more or less insignificant at ethanol concentrations below 5 % and became more significant with increasing ethanol concentration reaching very pronounced significance at ethanol concentrations above 10 %. Correspondingly fluorescence (Figure 2) was essentially constant whatever the ethanol concentration in spite of dramatically decreasing corresponding live cell count according to plate count (Figure 4) and percentage of live cells according to the live/dead staining (Figure 5) whereas luminescence (Figure 3) dropped dramatically essentially corresponding to the dramatic drop in plate count (Figure 4) and the percentage of live cells (Figure 5) with increased ethanol concentration.

[0039] The effect of serum complement on the growth and death of *E. coli* is shown in Figures 6 to 8. Fluorescence (Figure 6) and luminescence (Figure 7) are shown before (squares) and after (circles) incubation for 90 minutes with serum complement. Fluorescence (Figure 6) is

slightly increased, during incubation regardless of the concentration of serum, whereas luminescence (Figure 7) decreases during incubation with increasing serum concentration. The decrease of luminescence during incubation with increasing concentrations of serum correlates clearly with the percentage of cells alive after incubation (Figure 8).

CLAIMS

1. A method to enable the assessment of the growth rate and death rate of a micro-organism within a chosen time period in an environment of interest by introducing into said micro-organism at least two reporter genes, which method is characterised in that

a) said reporter genes code for luminescent and/or fluorescent products and within said time period and environment at least two said products of the following are produced:

i) an essentially stable product produced in a, within the environment of interest, essentially known proportion to the total amount of cells of said micro-organism that are or have been alive within said chosen time period,

ii) a product present in said environment of interest in an essentially known proportion to the amount of cells alive at any moment within said chosen time period, and

iii) an essentially stable product produced in a, within the environment of interest, essentially known proportion to the total amount of cells of said micro-organism that have died within said chosen time period, and said products can be measured through their luminescence and/or fluorescence;

b) said micro-organism is incubated within the environment of interest and said luminescence and/or fluorescence is detected after said chosen time period, and

c) the growth and death rate of the said micro-organism is assessed based on at least two of the following:

i) the known proportion of luminescence or fluorescence to the amount of cells alive after any said chosen time period,

ii) the known proportion of luminescence or fluorescence to the total amount of cells that are or have been alive within any said chosen time period, and

iii) the known proportion of luminescence or fluorescence to the total amount of cells that have died within any said chosen time period.

2. The method according to claim 1 characterised in that said micro-organism is a gram negative bacteria, e.g. *Escherichia coli*.

3. The method according to claim 1 [or 2] characterised in that
- a) one reporter gene coding for a luminescent product is luciferase, which is used for the determination of amount of cells alive at any moment within said chosen time period, and
 - b) another reporter gene coding for a fluorescent product is green fluorescent protein (GFP), which is used for the determination of total amount of cells of said micro-organism that are or have been alive within said chosen time period.
4. The method according to claim 1 [or 2] characterised in that said reporter genes are introduced into said micro-organism in a plasmid.
5. The [A] method according to [the methods of] claim 3 [or 4] characterised in that said plasmid is pGFP+luc* (SEQ ID NO: 1).
6. The method according to claim 2 characterised in that
- a) one reporter gene coding for a luminescent product is luciferase, which is used for the determination of amount of cells alive at any moment within said chosen time period, and
 - b) another reporter gene coding for a fluorescent product is green fluorescent protein (GFP), which is used for the determination of total amount of cells of said micro-organism that are or have been alive within said chosen time period.
7. The method according to claim 2 characterised in that said reporter genes are introduced into said micro-organism in a plasmid.
8. The method according to claim 4 characterised in that said plasmid is pGFP+luc* (SEQ ID NO: 1).
9. The method according to claim 6 characterised in that said plasmid is pGFP+luc* (SEQ ID NO: 1).

10. The method according to claim 7 characterised in that said plasmid is pGFP+luc* (SEQ ID NO: 1).

ABSTRACT

[0040] A method to enable the assessment of the growth rate and death rate of a micro-organism within a chosen time period in an environment of interest. The method is characterised in that

5 a) two reporter genes are introduced to said micro-organism wherein, the reporter genes used code for luminescent and/or fluorescent products and at least two of the following products: an essentially stable product produced in an essentially known proportion to the total amount of cells of said micro-organism that are or have been alive within said chosen time period; a product present in an essentially known proportion to the amount of cells alive at any
10 moment within said chosen time period; and an essentially stable product produced in an essentially known proportion to the total amount of cells of the said micro-organism that have died within said chosen time period, and said products can be measured through their luminescence and/or fluorescence;

 b) the said micro-organism is incubated and said luminescence and/or fluorescence
15 is detected after said chosen time periods, and

 c) the growth and death rate of the said micro-organism is assessed based on at least two of the following: the known proportion of luminescence or fluorescence to the amount of cells alive after any said chosen time period; the known proportion of luminescence or fluorescence to the total amount of cells that are or have been alive within any said chosen time
20 period; and the known proportion of luminescence or fluorescence to the total amount of cells that have died within any said chosen time period.

5/12/10

TITLE OF THE INVENTION

A METHOD TO ENABLE ASSESSMENT OF GROWTH AND DEATH OF MICRO-ORGANISMS

5 CROSS-REFERENCE TO RELATED APPLICATION

[0001] The present application is a national stage filing under 35 U.S.C. §371 of PCT/FI00/00507 filed on 7 June 2000 and claims priority under 35 U.S.C. §119 to Finland patent application No. 991296 filed on 7 June 1999.

10 [0002] This invention relates to a method to enable the assessment of growth and death of a micro-organism within a chosen time period in an environment of interest.

BACKGROUND OF THE INVENTION

[0003] When studying growth and death of a micro-organism under the influence of specific environments, e.g. production and storage environments that e.g. could or could not be refrigerated, or involving chemicals or matrixes, e.g. antibiotics, microbial toxins, heavy metals and serum complement, microbial cultures are most often incubated for hours or days. In these circumstances death and growth occur simultaneously. If additionally some of the cells lyse, e.g. when analysing the serum complement, it is difficult to know to what one should compare the amount of living cells at the end of the experiment. Convenient methods to determine the number of living cells, e.g. by measuring luciferase bioluminescence, are known but if no more information is available it is impossible to assess to what extent growth or/and death of the micro-organisms takes or has taken place.

25 [0004] Growth rates and death rates of micro-organisms in specific environments are of interest in many areas. Death rates and growth rates of micro-organisms and especially harmful and/or pathogenic micro-organisms are of importance in risk assessments of products of the pharmaceutical industry and products for human consumption with regard to their production, storage and distribution to the consumers. Knowledge of death and growth rates of micro-organisms are of particular importance in specific applications such as in the development of
30 antibiotics, disinfectants and bactericidal products or monitoring of sterilisation, disinfection and cleaning processes.

[0005] Reporter genes coding for luminescent or/and fluorescent products have been introduced to micro-organisms to enable the assessment of the quantity or survival of living

0980585-030420

micro-organisms (WO 96/23898, WO 98/14605, WO 98/30715, WO 98/36081, US 5,824,468). Even simultaneous use of luminescent and fluorescent markers has been used (Fratamico et al., Journal of Food Protection, Vol 50 No 10, 1997, 1167–1173). Luminescent and fluorescent markers have, however, only been used as markers for survival of micro-organisms and the use of two different markers within one micro-organism enabling the differentiation between growth and death rates has not been reported.

OBJECT AND SUMMARY OF THE INVENTION

[0006] The object of the present invention is to provide a method to enable the assessment of the growth and death of a micro-organism within a chosen time period in an environment of interest by introducing into said micro-organism at least two reporter genes. The method is characterised in that

- a) said reporter genes code for luminescent and/or fluorescent products and within said time period and environment at least two said products of the following are produced:
 - i) an essentially stable product produced in a, within the environment of interest, essentially known proportion to the total amount of cells of said micro-organism that are or have been alive within said chosen time period,
 - ii) a product present in said environment of interest in an essentially known proportion to the amount of cells alive at any moment within said chosen time period and
 - iii) an essentially stable product produced in a, within the environment of interest, essentially known proportion to the total amount of cells of said micro-organism that have died within said chosen time period,
 and said products can be measured through their luminescence and/or fluorescence;
- b) said micro-organism is incubated within the environment of interest and said luminescence and/or fluorescence is detected after said chosen time period, and
- c) the growth and death rate of the said micro-organism is assessed based on at least two of the following:

- i) the known proportion of luminescence or fluorescence to the amount of cells alive after any said chosen time period,
- ii) the known proportion of luminescence or fluorescence to the total amount of cells that are or have been alive within any said chosen time period, and
- iii) the known proportion of luminescence or fluorescence to the total amount of cells that have died within any said chosen time period.

BRIEF DESCRIPTION OF THE DRAWINGS

[0007] Figure 1 shows plasmid pGFP+luc* including genes for both GFP and firefly luciferase.

[0008] Figure 2 shows fluorescence during growth phase of *E. coli* with plasmid pGFP+luc* at 30 °C as a function of the concentration of ethanol in the cell culture.

[0009] Figure 3 shows luminescence during growth phase of *E. coli* with plasmid pGFP+luc* at 30 °C as a function of the concentration of ethanol in the cell culture.

[0010] Figure 4 shows the amount of living cells, i.e. colony forming units, according to plating during growth phase of *E. coli* with plasmid pGFP+luc* at 30 °C as a function of the concentration of ethanol in the cell culture.

[0011] Figure 5 shows the percentage of living cells according to live/dead staining and flow cytometric analysis during growth phase of *E. coli* with plasmid pGFP+luc* at 30 °C as a function of the concentration of ethanol in the cell culture.

[0012] Figure 6 shows fluorescence before and after incubation with serum complement during growth phase of *E. coli* with plasmid pGFP+luc* at 30 °C as a function of the concentration of serum complement in the cell culture.

[0013] Figure 7 shows luminescence before and after incubation with serum complement during growth phase of *E. coli* with plasmid pGFP+luc* at 30 °C as a function of the concentration of serum complement in the cell culture.

[0014] Figure 8 shows the percentage of living cells according to plating during growth phase of *E. coli* with plasmid pGFP+luc* at 30 °C as a function of the concentration of serum complement in the cell culture.

DETAILED DESCRIPTION OF THE INVENTION

[0015] The method according to the present invention can be used to assess the growth and death rate of a micro-organism within a chosen time period in any particular environment of interest. The method is applicable if two different marker genes can be introduced to the micro-organism that code for luminescent and/or fluorescent products, and the products of these fulfil at least two of the following three criteria:

a) a said luminescent product luminesces or said fluorescent product fluoresces in an essentially known proportion to the amount of cells of said micro-organism alive within said chosen time period ;

b) a said luminescent product luminesces or said fluorescent product fluoresces in an essentially known proportion to the amount of cells of said micro-organism that are or have been alive within said chosen time period, and

c) a said luminescent product luminesces or said fluorescent product fluoresces in an essentially known proportion to the amount of cells of said micro-organism that have died within said chosen time period.

[0016] In the present application the concept "micro-organism" means any micro-organism into which marker genes can be introduced so, that they will function according to the invention. "Micro-organism" can therefore stand for bacteria, yeast or fungi.

[0017] The concept of "introducing a marker gene into a micro-organism" means any method by which a marker gene can be made to function within the micro-organism according to the invention. One way of introducing marker genes into micro-organism is by constructing a recombinant strain. This can be done by transforming a strain with a plasmid including the marker genes. An alternative way to introduce reporter genes to bacteria is to utilise transposable elements. In this technique, reporter genes are inserted between insertion sequences in a delivery plasmid. The plasmid is then introduced to a cell by e.g. conjugation of transformation, and once inside the cell, genes surrounded by the insertion sequences are integrated into bacterial chromosome. Integration is stable, i.e. there is no need for a selectable marker such as antibiotic resistance.

[0018] Assessment of the growth rate and death rate of a micro-organism can be of interest in many specific environments. Within pharmaceutical research the effect of different drugs and candidates for drugs, e.g. antibiotics, on the survival of pathogenic, but also the

beneficial micro-organisms of the gut, is of interest. Thus the ultimate interest is in the behaviour of these micro-organisms in a physiological environment affected by drugs.

[0019] Another vast area where the possibility of assessing growth and death rate of specific micro-organisms is of interest is that of production, processing, storage and distribution of all products for human consumption. In this area the behaviour of pathogenic or potentially harmful micro-organisms in the different environments of the life cycle of these products is of special interest and involves many different aspects such as the influence of temperature, humidity or light and the possible use of preservatives etc.

[0020] Additionally growth and death rates of micro-organisms can be of interest for environmental evaluations e.g. when evaluating the effect of emissions into the environment.

[0021] Luminescent or fluorescent products coded by reporter genes in different embodiments of this invention can vary as long as their proportion to either the total amount of cells alive, to cells that are or have been alive, or to cells that have died is essentially known. Growth and death rate can be assessed if two of the following: cells alive, cells that are or have been alive, or cells that have died can be determined. Thus luminescence and/or fluorescence measured can be e.g. of a product which is expressed e.g. constitutively or triggered by a specific phase (e.g. replication or death) of the lifecycle of each cell, is stable or labile or which luminescence or fluorescence is dependant on a factor that relates e.g. to a specific phase of the lifecycle of each cell. Depending on the individual characteristics of said product—how produced, stable or labile, possible dependence of its luminescence or fluorescence of said factors etc.—the measured luminescence or fluorescence can be in proportion to one of the three unknown of which two must be known to be able to assess the growth rate and death rate of said cells.

[0022] According to one specific embodiment of the invention assessment of the growth and death rate of an *Escherichia coli* strain under the influence of different chemicals or matrixes was enabled by constructing a recombinant strain, which expresses both luciferase and GFP. Altogether the effect of a number of different chemicals and matrixes, such as CdCl₂, ethanol, the antibiotics chloramphenicol, rifampicin, and tetracyclin, as well as serum complement on said recombinant *E. coli* strain was tested and found applicable.

[0023] The invention will be described in more detail by the following study in which the growth rate and death rate of a recombinant *Escherichia coli* strain, which expresses both luciferase and GFP, is assessed under the influence of ethanol or serum complement.

Summary of the study

[0024] Genes for luciferase and green fluorescent protein have recently raised interest as reporter genes. Luciferase is an enzyme that produces luminescence in the presence of substrate luciferin, molecular oxygen and ATP. Green fluorescent protein (GFP), produces green fluorescence when excited with light. Many mutated forms of GFP have been introduced: some have different excitation and emission wavelengths from the wild type and some mutants form more stable proteins at higher temperatures.

[0025] We constructed a recombinant strain of *E. coli*, which expresses both luciferase and GFP. In our construction we used a mutant of GFP, which is more stable at temperatures over +30 °C and it matures quicker than the wild type. Luciferase was from North American firefly, *Photinus pyralis*.

[0026] The *E. coli* strain MC1061 was transformed with a plasmid including genes for both GFP and firefly luciferase. Figure 1 describes the plasmid in general. The sequence of the plasmid is disclosed in the sequence listing. Essential codings of the sequence are as follows:

lac promoter	95–199
GFP	289–1008
firefly luciferase	1044–2696
β-lactamase	3251–4111

[0027] In our construct, see Figure 1, the luciferase gene is situated next to the GFP gene and both genes are transcribed in the same direction. The transcription is started at the lac promoter in front of GFP. The lac promoter is constitutively active, because the MC1061 cells lack its repressor. The plasmid also has a gene for ampicillin resistance (β-lactamase).

[0028] The transformed *E. coli* strain was propagated under the influence of different concentrations of ethanol or serum complement.

Methods

Growth conditions

[0029] One colony from a pure culture plate was inoculated in 5 ml of LB-medium with ampicillin (100 µg/ml) and grown at +37 °C in a shaker, 250 rpm, for about three hours. After that, the number of cells per millilitre was determined with flow cytometry by using fluorescent spherical latex particles as a reference. One million cells were then removed to an erlenmeyer

with 50 ml of LB medium and ampicillin. The culture was grown over night in a shaker, 190 rpm, at room temperature to prevent the culture from growing into the stationary phase during the night. In the morning, the culture was transferred to and grown in a shaker, 330 rpm, until the stationary phase was reached or used after growth at +30 °C for about 1 h to study the influence of ethanol or serum complement as described below.

Influence of chemicals on the propagation of *E. coli*

[0030] The culture obtained as described above was used to study the influence of ethanol or serum complement as follows:

Ethanol

[0031] Ethanol (Aa, Primalco Oy) was diluted into pure water to obtain concentrations of 50, 45, 25, 10, 5, 1 and 0 % of ethanol when 500 µl of said dilution was added to 500 µl of said culture in an eppendorf tube. The mixture was vortexed and incubated for 5 minutes before measuring fluorescence and luminescence. Live cells were again counted by plating and also by live/dead staining. In the live/dead protocol used the stain *cyto 9* stains all cells whereas propidium iodide stains only the dead cells. After staining, cells are passed through a flow cytometer, with which dead and live cells can be differentiated and their proportion determined. (Virta et al. (1998) Appl. Environ. Microbiol. 64: 515–519.)

Serum complement

[0032] The influence of serum complement on the said recombinant *E. coli* strain was studied using an incubation time of 90 min as described for a different recombinant *E. coli* strain used in Virta et al. (1998) Appl. Environ. Microbiol. 64: 515–519.

Fluorescence and luminescence measurements

[0033] The measurements were done with a combined fluoro- and luminometer, Fluoroscan Ascent FL, provided by Labsystems Ltd. (Helsinki, Finland). Cell growth was simultaneously followed with a flow cytometer.

[0034] For the measurements, 100 µl of bacterial culture was pipetted into the microtiter plate wells. Fluorescence was measured using 485 nm for excitation and 510 nm for emission. Measuring time was 20 ms. After the fluorescence measurement 100 µl of luciferin in 0.1 M citric acid-sodium citrate buffer (pH 5.0) was dispensed into the wells and the plate was shaken

for two minutes (shaking diameter 1 mm, 1 020 rpm), after which luminescence was recorded with a measuring time of 1000 ms.

Plating

[0035] Samples for plating were diluted 10^2 to 10^7 fold with 150 mM NaCl and plated onto L agar plates (L broth containing 1.6 % agar). Colonies were counted after overnight incubation at 37 °C.

Live/dead staining and Flow cytometric analysis

[0036] Bacteria from 1 000 µl of cell culture were used for live/dead staining and flow cytometric analysis using a LIVE/DEAD BacLight bacterial viability kit (catalogue no. L-7005) for microscopy and quantitative analysis obtained from Molecular Probes Europe (Leiden, The Netherlands) and Fluoresbrite beads (diameter, 1.8 µm) obtained from Polysciences Inc. (Warrington, Pa.) as described in Virta et al. (1998) Appl. Environ. Microbiol. 64: 515–519.

Results

[0037] When the cultures were transferred to +30 °C, the cells grew logarithmically for 1-4 hours depending on the initial cell concentration. Luminescence and fluorescence rose logarithmically and were essentially constant per cell. Thus cell number could be assessed based on luminescence or fluorescence.

[0038] When ethanol was added in different concentrations to the growth medium (see Figures 4 and 5) death was, after a very short incubation period of 5 min, more or less insignificant at ethanol concentrations below 5 % and became more significant with increasing ethanol concentration reaching very pronounced significance at ethanol concentrations above 10 %. Correspondingly fluorescence (Figure 2) was essentially constant whatever the ethanol concentration in spite of dramatically decreasing corresponding live cell count according to plate count (Figure 4) and percentage of live cells according to the live/dead staining (Figure 5) whereas luminescence (Figure 3) dropped dramatically essentially corresponding to the dramatic drop in plate count (Figure 4) and the percentage of live cells (Figure 5) with increased ethanol concentration.

[0039] The effect of serum complement on the growth and death of *E. coli* is shown in Figures 6 to 8. Fluorescence (Figure 6) and luminescence (Figure 7) are shown before (squares) and after (circles) incubation for 90 minutes with serum complement. Fluorescence (Figure 6) is

slightly increased, during incubation regardless of the concentration of serum, whereas luminescence (Figure 7) decreases during incubation with increasing serum concentration. The decrease of luminescence during incubation with increasing concentrations of serum correlates clearly with the percentage of cells alive after incubation (Figure 8).

CLAIMS

1. A method to enable the assessment of the growth rate and death rate of a micro-organism within a chosen time period in an environment of interest by introducing into said micro-organism at least two reporter genes, which method is characterised in that
 - a) said reporter genes code for luminescent and/or fluorescent products and within said time period and environment at least two said products of the following are produced:
 - i) an essentially stable product produced in a, within the environment of interest, essentially known proportion to the total amount of cells of said micro-organism that are or have been alive within said chosen time period,
 - ii) a product present in said environment of interest in an essentially known proportion to the amount of cells alive at any moment within said chosen time period, and
 - iii) an essentially stable product produced in a, within the environment of interest, essentially known proportion to the total amount of cells of said micro-organism that have died within said chosen time period,
 and said products can be measured through their luminescence and/or fluorescence;
 - b) said micro-organism is incubated within the environment of interest and said luminescence and/or fluorescence is detected after said chosen time period, and
 - c) the growth and death rate of the said micro-organism is assessed based on at least two of the following:
 - i) the known proportion of luminescence or fluorescence to the amount of cells alive after any said chosen time period,
 - ii) the known proportion of luminescence or fluorescence to the total amount of cells that are or have been alive within any said chosen time period, and
 - iii) the known proportion of luminescence or fluorescence to the total amount of cells that have died within any said chosen time period.
2. The method according to claim 1 characterised in that said micro-organism is a gram negative bacteria, e.g. *Escherichia coli*.

3. The method according to claim 1 characterised in that
- a) one reporter gene coding for a luminescent product is luciferase, which is used for the determination of amount of cells alive at any moment within said chosen time period, and
 - b) another reporter gene coding for a fluorescent product is green fluorescent protein (GFP), which is used for the determination of total amount of cells of said micro-organism that are or have been alive within said chosen time period.
4. The method according to claim 1 characterised in that said reporter genes are introduced into said micro-organism in a plasmid.
5. The method according to claim 3 characterised in that said plasmid is pGFP+luc* (SEQ ID NO: 1).
6. The method according to claim 2 characterised in that
- a) one reporter gene coding for a luminescent product is luciferase, which is used for the determination of amount of cells alive at any moment within said chosen time period, and
 - b) another reporter gene coding for a fluorescent product is green fluorescent protein (GFP), which is used for the determination of total amount of cells of said micro-organism that are or have been alive within said chosen time period.
7. The method according to claim 2 characterised in that said reporter genes are introduced into said micro-organism in a plasmid.
8. The method according to claim 4 characterised in that said plasmid is pGFP+luc* (SEQ ID NO: 1).
9. The method according to claim 6 characterised in that said plasmid is pGFP+luc* (SEQ ID NO: 1).

10. The method according to claim 7 characterised in that said plasmid is pGFP+luc* (SEQ ID NO: 1).

2040E0" 58508660

ABSTRACT

[0040] A method to enable the assessment of the growth rate and death rate of a micro-organism within a chosen time period in an environment of interest. The method is characterised in that

5 a) two reporter genes are introduced to said micro-organism wherein, the reporter genes used code for luminescent and/or fluorescent products and at least two of the following products: an essentially stable product produced in an essentially known proportion to the total amount of cells of said micro-organism that are or have been alive within said chosen time period; a product present in an essentially known proportion to the amount of cells alive at any
10 moment within said chosen time period; and an essentially stable product produced in an essentially known proportion to the total amount of cells of the said micro-organism that have died within said chosen time period, and said products can be measured through their luminescence and/or fluorescence;

b) the said micro-organism is incubated and said luminescence and/or fluorescence
15 is detected after said chosen time periods, and

c) the growth and death rate of the said micro-organism is assessed based on at least two of the following: the known proportion of luminescence or fluorescence to the amount of cells alive after any said chosen time period; the known proportion of luminescence or fluorescence to the total amount of cells that are or have been alive within any said chosen time
20 period; and the known proportion of luminescence or fluorescence to the total amount of cells that have died within any said chosen time period.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7




Figure 8

09/980585-030402

<p align="center">DECLARATION AND POWER OF ATTORNEY FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)</p> <p> <input type="checkbox"/> Declaration Submitted with Initial Filing <input type="checkbox"/> Declaration Submitted after Initial Filing </p>	Attorney Docket No.	
	First Named Inventor	
	COMPLETE IF KNOWN	
	Application Number	
	Filing Date	
	Group Art Unit	
	Examiner Name	

As a below named inventor, I hereby declare that:

My residence, mailing address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: A method to enable assessment of growth and death of micro-organisms

 the specification of which is attached hereto.

X the specification of which was filed on December 4, 2001 as United States Application Number 09/980,585 or PCT International Application Number PCT/FI00/00507 and was amended on December 4, 2001

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Numbers	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
991296	FI	06/07/1999	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

I or we hereby appoint the registered practitioner(s) associated with Customer No. **6449** to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith. Direct all correspondence to Customer Number **6449**.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF SOLE OR FIRST INVENTOR:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name <u>Esa-Matti</u> (first and middle [if any])		Family Name <u>Lilius</u> or Surname	
Inventor's Signature <u>[Signature]</u>		Date <u>21.1.2002</u>	
Residence: City <u>Kaarina</u>	State <u>FIN</u>	Country <u>Finland</u>	Citizenship <u>Finnish</u>
Mailing Address <u>Vaakunatie 10</u>			
Mailing Address			
City <u>Kaarina</u>	State	Zip <u>FIN-20780</u>	Country <u>Finland</u>
NAME OF SECOND INVENTOR:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name <u>Marko</u> (first and middle [if any])		Family Name <u>Virta</u> or Surname	
Inventor's Signature <u>[Signature]</u>		Date <u>21.1.2002</u>	
Residence: City <u>Turku</u>	State	Country <u>Finland</u>	Citizenship <u>Finnish</u>
Mailing Address <u>Kauppiaskatu 10 D 59</u>			
Mailing Address			
City <u>Turku</u>	State	Zip <u>FIN-20100</u>	Country <u>Finland</u>
NAME OF THIRD INVENTOR:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle [if any])		Family Name or Surname	
Inventor's Signature		Date	
Residence: City	State	Country	Citizenship
Mailing Address			
Mailing Address			
City	State	Zip	Country

SEQUENCE LISTING

<110> LILIUS, Esa-Matti
VIRTA, Marko

<120> A Method to Enable Assessment of Growth and Death of Micro-organisms

<130> 2328-124

<150> PCT/FI00/00507
<151> 2000-06-07

<150> FI 991296
<151> 1999-06-07

<160> 4

<170> PatentIn version 3.0

<210> 1
<211> 5051
<212> DNA
<213> Artificial

<220>
<223> pGFP+Luc* plasmid

<220>
<221> promoter
<222> (95)..(199)
<223> lac promoter

<220>
<221> CDS
<222> (289)..(1005)
<223> GFP

<220>
<221> CDS
<222> (1044)..(2693)
<223> firefly luciferase

<220>
<221> CDS
<222> (3251)..(4108)
<223> beta-lactamase

<400> 1
agcgcccaat acgcaaaccg cctctccccg cgcgttgcc gattcattaa tgcagctggc 60
acgacaggtt tcccgactgg aaagcgggca gtgagcgcaa cgcaattaat gtgagttagc 120
tcaactcatta ggcaccccag gctttacact ttatgcttcc ggctcgtagt ttgtgtggaa 180
ttgtgagcgg ataacaattt cacacaggaa acagctatga ccatgattac gccaaagcttg 240
catgectgca ggtcgactct agaggatccc cgggtaccgg tcgccacc atg gtg agc 297
Met Val Ser
1
aag ggc gag gag ctg ttc acc ggg gtg gtg ccc atc ctg gtc gag ctg 345
Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val Glu Leu
5 10 15

0980585-0340

gac ggc gac gta aac ggc cac aag ttc agc gtg tcc ggc gag ggc gag 393
 Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu Gly Glu
 20 25 30 35

ggc gat gcc acc tac ggc aag ctg acc ctg aag ttc atc tgc acc acc 441
 Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys Thr Thr
 40 45 50

ggc aag ctg ccc gtg ccc tgg ccc acc ctc gtg acc acc ctg acc tac 489
 Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Leu Thr Tyr
 55 60 65

ggc gtg cag tgc ttc agc cgc tac ccc gac cac atg aag cag cac gac 537
 Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Gln His Asp
 70 75 80

ttc ttc aag tcc gcc atg ccc gaa ggc tac gtc cag gag cgc acc atc 585
 Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg Thr Ile
 85 90 95

ttc ttc aag gac gac ggc aac tac aag acc cgc gcc gag gtg aag ttc 633
 Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val Lys Phe
 100 105 110 115

gag ggc gac acc ctg gtg aac cgc atc gag ctg aag ggc atc gac ttc 681
 Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile Asp Phe
 120 125 130

aag gag gac ggc aac atc ctg ggg cac aag ctg gag tac aac tac aac 729
 Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn Tyr Asn
 135 140 145

agc cac aac gtc tat atc atg gcc gac aag cag aag aac ggc atc aag 777
 Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly Ile Lys
 150 155 160

gtg aac ttc aag atc cgc cac aac atc gag gac ggc agc gtg cag ctc 825
 Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val Gln Leu
 165 170 175

gcc gac cac tac cag cag aac acc ccc atc ggc gac ggc ccc gtg ctg 873
 Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro Val Leu
 180 185 190 195

ctg ccc gac aac cac tac ctg agc acc cag tcc gcc ctg agc aaa gac 921
 Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser Lys Asp
 200 205 210

ccc aac gag aag cgc gat cac atg gtc ctg ctg gag ttc gtg acc gcc 969
 Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val Thr Ala
 215 220 225

gcc ggg atc act ctc ggc atg gac gag ctg tac aag taaagcggcc 1015
 Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys
 230 235

gctctagaac tagtggatcc cccgtacc atg gaa gac gcc aaa aac ata aag 1067
 Met Glu Asp Ala Lys Asn Ile Lys
 240 245

aaa ggc ccg gcg cca ttc tat ccg cta gag gat gga acc gct gga gag 1115
 Lys Gly Pro Ala Pro Phe Tyr Pro Leu Glu Asp Gly Thr Ala Gly Glu

00980585 030402

250						255						260						
caa	ctg	cat	aag	gct	atg	aag	aga	tac	gcc	ctg	gtt	cct	gga	aca	att	1163		
Gln	Leu	His	Lys	Ala	Met	Lys	Arg	Tyr	Ala	Leu	Val	Pro	Gly	Thr	Ile			
	265						270				275							
gct	ttt	aca	gat	gca	cat	atc	gag	gtg	aac	atc	acg	tac	gcg	gaa	tac	1211		
Ala	Phe	Thr	Asp	Ala	His	Ile	Glu	Val	Asn	Ile	Thr	Tyr	Ala	Glu	Tyr			
280					285					290					295			
ttc	gaa	atg	tcc	gtt	cgg	ttg	gca	gaa	gct	atg	aaa	cga	tat	ggg	ctg	1259		
Phe	Glu	Met	Ser	Val	Arg	Leu	Ala	Glu	Ala	Met	Lys	Arg	Tyr	Gly	Leu			
				300					305					310				
aat	aca	aat	cac	aga	atc	gtc	gta	tgc	agt	gaa	aac	tct	ctt	caa	ttc	1307		
Asn	Thr	Asn	His	Arg	Ile	Val	Val	Cys	Ser	Glu	Asn	Ser	Leu	Gln	Phe			
			315					320					325					
ttt	atg	ccg	gtg	ttg	ggc	gcg	tta	ttt	atc	gga	gtt	gca	gtt	gcg	ccc	1355		
Phe	Met	Pro	Val	Leu	Gly	Ala	Leu	Phe	Ile	Gly	Val	Ala	Val	Ala	Pro			
		330					335					340						
gcg	aac	gac	att	tat	aat	gaa	cgt	gaa	ttg	ctc	aac	agt	atg	aac	att	1403		
Ala	Asn	Asp	Ile	Tyr	Asn	Glu	Arg	Glu	Leu	Leu	Asn	Ser	Met	Asn	Ile			
	345					350					355							
tcg	cag	cct	acc	gta	gtg	ttt	gtt	tcc	aaa	aag	ggg	ttg	caa	aaa	att	1451		
Ser	Gln	Pro	Thr	Val	Val	Phe	Val	Ser	Lys	Lys	Gly	Leu	Gln	Lys	Ile			
360					365					370					375			
ttg	aac	gtg	caa	aaa	aaa	tta	cca	ata	atc	cag	aaa	att	att	atc	atg	1499		
Leu	Asn	Val	Gln	Lys	Lys	Leu	Pro	Ile	Ile	Gln	Lys	Ile	Ile	Ile	Met			
				380					385					390				
gat	tct	aaa	acg	gat	tac	cag	gga	ttt	cag	tcg	atg	tac	acg	ttc	gtc	1547		
Asp	Ser	Lys	Thr	Asp	Tyr	Gln	Gly	Phe	Gln	Ser	Met	Tyr	Thr	Phe	Val			
			395				400						405					
aca	tct	cat	cta	cct	ccc	ggt	ttt	aat	gaa	tac	gat	ttt	gta	cca	gag	1595		
Thr	Ser	His	Leu	Pro	Pro	Gly	Phe	Asn	Glu	Tyr	Asp	Phe	Val	Pro	Glu			
		410					415					420						
tcc	ttt	gat	cgt	gac	aaa	aca	att	gca	ctg	ata	atg	aac	tcc	tct	gga	1643		
Ser	Phe	Asp	Arg	Asp	Lys	Thr	Ile	Ala	Leu	Ile	Met	Asn	Ser	Ser	Gly			
	425					430					435							
tct	act	ggg	tta	cct	aag	ggt	gtg	gcc	ctt	ccg	cat	aga	act	gcc	tgc	1691		
Ser	Thr	Gly	Leu	Pro	Lys	Gly	Val	Ala	Leu	Pro	His	Arg	Thr	Ala	Cys			
440					445					450					455			
gtc	aga	ttc	tcg	cat	gcc	aga	gat	cct	att	ttt	ggc	aat	caa	atc	att	1739		
Val	Arg	Phe	Ser	His	Ala	Arg	Asp	Pro	Ile	Phe	Gly	Asn	Gln	Ile	Ile			
				460														

505	510	515	
aaa att caa agt gcy ttg cta gta cca acc cta ttt tca ttc ttc gcc Lys Ile Gln Ser Ala Leu Leu Val Pro Thr Leu Phe Ser Phe Phe Ala 520 525 530 535			1931
aaa agc act ctg att gac aaa tac gat tta tct aat tta cac gaa att Lys Ser Thr Leu Ile Asp Lys Tyr Asp Leu Ser Asn Leu His Glu Ile 540 545 550			1979
gct tct ggg ggc gca cct ctt tct aaa gaa gtc ggg gaa gcy gtt gca Ala Ser Gly Gly Ala Pro Leu Ser Lys Glu Val Gly Glu Ala Val Ala 555 560 565			2027
aaa cgc ttc cat ctt cca ggg ata cga caa gga tat ggg ctc act gag Lys Arg Phe His Leu Pro Gly Ile Arg Gln Gly Tyr Gly Leu Thr Glu 570 575 580			2075
act aca tca gct att ctg att aca ccc gag ggg gat gat aaa ccg ggc Thr Thr Ser Ala Ile Leu Ile Thr Pro Glu Gly Asp Asp Lys Pro Gly 585 590 595			2123
gcy gtc ggt aaa gtt gtt cca ttt ttt gaa gcy aag gtt gtg gat ctg Ala Val Gly Lys Val Val Pro Phe Phe Glu Ala Lys Val Val Asp Leu 600 605 610 615			2171
gat acc ggg aaa acg ctg ggc gtt aat cag aga ggc gaa tta tgt gtc Asp Thr Gly Lys Thr Leu Gly Val Asn Gln Arg Gly Glu Leu Cys Val 620 625 630			2219
aga gga cct atg att atg tcc ggt tat gta aac aat ccg gaa gcy acc Arg Gly Pro Met Ile Met Ser Gly Tyr Val Asn Asn Pro Glu Ala Thr 635 640 645			2267
aac gcc ttg att gac aag gat gga tgg cta cat tct gga gac ata gct Asn Ala Leu Ile Asp Lys Asp Gly Trp Leu His Ser Gly Asp Ile Ala 650 655 660			2315
tac tgg gac gaa gac gaa cac ttc ttc ata gtt gac cgc ttg aag tct Tyr Trp Asp Glu Asp Glu His Phe Phe Ile Val Asp Arg Leu Lys Ser 665 670 675			2363
tta att aaa tac aaa gga tac cag gtg gcc ccc gct gaa ttg gag tct Leu Ile Lys Tyr Lys Gly Tyr Gln Val Ala Pro Ala Glu Leu Glu Ser 680 685 690 695			2411
ata ttg tta caa cac ccc aac atc ttc gac gcy ggc gtg gca ggt ctt Ile Leu Leu Gln His Pro Asn Ile Phe Asp Ala Gly Val Ala Gly Leu 700 705 710			2459
ccc gac gat gac gcc ggt gaa ctt ccc gcc gcc gtt gtt gtt ttg gag Pro Asp Asp Asp Ala Gly Glu Leu Pro Ala Ala Val Val Val Leu Glu 715 720 725			2507
cac gga aag acg atg acg gaa aaa gag atc gtg gat tac gtc gcc agt His Gly Lys Thr Met Thr Glu Lys Glu Ile Val Asp Tyr Val Ala Ser 730 735 740			2555
caa gta aca acc gcc aaa aag ttg cgc gga gga gtt gtg ttt gtg gac Gln Val Thr Thr Ala Lys Lys Leu Arg Gly Gly Val Val Phe Val Asp 745 750 755			2603
gaa gta ccg aaa ggt ctt acc gga aaa ctc gac gca aga aaa atc aga			2651

059805555 030403

Glu Val Pro Lys Gly Leu Thr Gly Lys Leu Asp Ala Arg Lys Ile Arg
 760 765 770 775
 gag atc ctc ata aag gcc aag aag ggc gga aag tcc aaa ttg 2693
 Glu Ile Leu Ile Lys Ala Lys Lys Gly Gly Lys Ser Lys Leu
 780 785
 taaaatgtaa ctgtattcag cgatgacgaa attcttagct attgtaatac tctaggggct 2753
 gcaggaattc gatatacagc ttatcgatac cgtcgacctc gagggggggc cctttcgtct 2813
 cgcgcgtttc ggtgatgacg gtgaaaacct ctgacacatg cagctcccgg agacggtcac 2873
 agcttgtctg taagcggatg ccgggagcag acaagcccgt cagggcgcgct cagcgggtgt 2933
 tggcgggtgt cggggctggc ttaactatgc ggcatcagag cagattgtac tgagagtgca 2993
 ccatatgcgg tgtgaaatac cgcacagatg cgtaaggaga aaataccgca tcaggcggcc 3053
 ttaagggcct cgtgatacgc ctatTTTTat aggttaatgt catgataata atggtttctt 3113
 agacgtcagg tggcactttt cggggaaatg tgcgcggaac ccctatttgt ttatTTTTct 3173
 aaatacattc aaatatgtat ccgctcatga gacaataacc ctgataaatg cttcaataat 3233
 attgaaaaag gaagagt atg agt att caa cat ttc cgt gtc gcc ctt att 3283
 Met Ser Ile Gln His Phe Arg Val Ala Leu Ile
 790 795 800
 ccc ttt ttt gcg gca ttt tgc ctt cct gtt ttt gct cac cca gaa acg 3331
 Pro Phe Phe Ala Ala Phe Cys Leu Pro Val Phe Ala His Pro Glu Thr
 805 810 815
 ctg gtg aaa gta aaa gat gct gaa gat cag ttg ggt gca cga gtg ggt 3379
 Leu Val Lys Val Lys Asp Ala Glu Asp Gln Leu Gly Ala Arg Val Gly
 820 825 830
 tac atc gaa ctg gat ctc aac agc ggt aag atc ctt gag agt ttt cgc 3427
 Tyr Ile Glu Leu Asp Leu Asn Ser Gly Lys Ile Leu Glu Ser Phe Arg
 835 840 845
 ccc gaa gaa cgt ttt cca atg atg agc act ttt aaa gtt ctg cta tgt 3475
 Pro Glu Glu Arg Phe Pro Met Met Ser Thr Phe Lys Val Leu Leu Cys
 850 855 860
 ggc gcg gta tta tcc cgt att gac gcc ggg caa gag caa ctc ggt cgc 3523
 Gly Ala Val Leu Ser Arg Ile Asp Ala Gly Gln Glu Gln Leu Gly Arg
 865 870 875 880
 cgc ata cac tat tct cag aat gac ttg gtt gag tac tca cca gtc aca 3571
 Arg Ile His Tyr Ser Gln Asn Asp Leu Val Glu Tyr Ser Pro Val Thr
 885 890 895
 gaa aag cat ctt acg gat ggc atg aca gta aga gaa tta tgc agt gct 3619
 Glu Lys His Leu Thr Asp Gly Met Thr Val Arg Glu Leu Cys Ser Ala
 900 905 910
 gcc ata acc atg agt gat aac act gcg gcc aac tta ctt ctg aca acg 3667
 Ala Ile Thr Met Ser Asp Asn Thr Ala Ala Asn Leu Leu Leu Thr Thr
 915 920 925
 atc gga gga ccg aag gag cta acc gct ttt ttg cac aac atg ggg gat 3715
 Ile Gly Gly Pro Lys Glu Leu Thr Ala Phe Leu His Asn Met Gly Asp

00980585 030405
 204058 585866

930		935		940	
cat gta act cgc ctt gat cgt tgg gaa ccg gag ctg aat gaa gcc ata	3763				
His Val Thr Arg Leu Asp Arg Trp Glu Pro Glu Leu Asn Glu Ala Ile					
945		950		955	960
cca aac gac gag cgt gac acc acg atg cct gta gca atg gca aca acg	3811				
Pro Asn Asp Glu Arg Asp Thr Thr Met Pro Val Ala Met Ala Thr Thr					
		965		970	975
ttg cgc aaa cta tta act ggc gaa cta ctt act cta gct tcc cgg caa	3859				
Leu Arg Lys Leu Leu Thr Gly Glu Leu Leu Thr Leu Ala Ser Arg Gln					
		980		985	990
caa tta ata gac tgg atg gag gcg gat aaa gtt gca gga cca ctt ctg	3907				
Gln Leu Ile Asp Trp Met Glu Ala Asp Lys Val Ala Gly Pro Leu Leu					
		995	1000	1005	
cgc tcg gcc ctt ccg gct ggc tgg ttt att gct gat aaa tct gga	3952				
Arg Ser Ala Leu Pro Ala Gly Trp Phe Ile Ala Asp Lys Ser Gly					
		1010	1015	1020	
gcc ggt gag cgt ggg tct cgc ggt atc att gca gca ctg ggg cca	3997				
Ala Gly Glu Arg Gly Ser Arg Gly Ile Ile Ala Ala Leu Gly Pro					
		1025	1030	1035	
gat ggt aag ccc tcc cgt atc gta gtt atc tac acg acg ggg agt	4042				
Asp Gly Lys Pro Ser Arg Ile Val Val Ile Tyr Thr Thr Gly Ser					
		1040	1045	1050	
cag gca act atg gat gaa cga aat aga cag atc gct gag ata ggt	4087				
Gln Ala Thr Met Asp Glu Arg Asn Arg Gln Ile Ala Glu Ile Gly					
		1055	1060	1065	
gcc tca ctg att aag cat tgg taactgtcag accaagttta ctcatatata	4138				
Ala Ser Leu Ile Lys His Trp					
		1070	1075		
ctttagattg atttaaaact tcattttttaa tttaaaagga tctaggtgaa gatccttttt	4198				
gataatctca tgaccaaaat cccttaacgt gagttttcgt tccactgagc gtcagacccc	4258				
gtagaaaaga tcaaaggatc ttcttgagat ccttttttttc tgcgcgtaat ctgctgcttg	4318				
caaacaaaaa aaccaccyct accagcggtg gtttgtttgc cggatcaaga gctaccaact	4378				
ctttttccga aggtaactgg cttcagcaga gcgcagatac caaatactgt ccttctagtg	4438				
tagccgtagt taggccacca cttcaagaac tctgtagcac cgctacata cctcgctctg	4498				
ctaactcctgt taccagtggc tgctgccagt ggcgataagt cgtgtcttac cgggttgac	4558				
tcaagacgat agttaccgga taaggcgcag cggtcgggct gaacgggggg ttcgtgcaca	4618				
cagcccagct tggagcgaac gacctacacc gaactgagat acctacagcg tgagctatga	4678				
gaaagcgcca cgcttcccga agggagaaaag gcggacaggt atccggtaag cggcagggtc	4738				
ggaacaggag agcgcacgag ggagcttcca gggggaaaac cctggtatct ttatagtcct	4798				
gtcgggtttc gccacctctg acttgagcgt cgatttttgt gatgctcgtc agggggggcg	4858				
agcctatgga aaaacgccag caacgcggcc tttttacggt tcttggcctt ttgctggcct	4918				

tttgctcaca tggtctttcc tgcgttatcc cctgattctg tggataaccg tattaccgcc 4978
 tttgagttag ctgataaccgc tcgccgcagc cgaacgaccg agcgcagcga gtcagtgage 5038
 gaggaagcgg aag 5051

<210> 2
 <211> 239
 <212> PRT
 <213> Artificial

<400> 2

Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu
 1 5 10 15
 Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly
 20 25 30
 Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile
 35 40 45
 Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr
 50 55 60
 Leu Thr Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys
 65 70 75 80
 Gln His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu
 85 90 95
 Arg Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu
 100 105 110
 Val Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly
 115 120 125
 Ile Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr
 130 135 140
 Asn Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn
 145 150 155 160
 Gly Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser
 165 170 175
 Val Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly
 180 185 190
 Pro Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu
 195 200 205
 Ser Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe
 210 215 220
 Val Thr Ala Ala Gly Ile Thr Leu Gly Met Asp Glu Leu Tyr Lys
 225 230 235

<210> 3
 <211> 550
 <212> PRT
 <213> Artificial

<400> 3

09960585-030403

Met 1	Glu	Asp	Ala	Lys 5	Asn	Ile	Lys	Lys	Gly 10	Pro	Ala	Pro	Phe	Tyr 15	Pro
Leu	Glu	Asp	Gly 20	Thr	Ala	Gly	Glu	Gln 25	Leu	His	Lys	Ala	Met 30	Lys	Arg
Tyr	Ala	Leu 35	Val	Pro	Gly	Thr	Ile 40	Ala	Phe	Thr	Asp	Ala 45	His	Ile	Glu
Val	Asn 50	Ile	Thr	Tyr	Ala	Glu 55	Tyr	Phe	Glu	Met	Ser 60	Val	Arg	Leu	Ala
Glu 65	Ala	Met	Lys	Arg	Tyr 70	Gly	Leu	Asn	Thr	Asn 75	His	Arg	Ile	Val	Val 80
Cys	Ser	Glu	Asn 85	Ser	Leu	Gln	Phe	Phe	Met 90	Pro	Val	Leu	Gly 95	Ala	Leu
Phe	Ile	Gly	Val 100	Ala	Val	Ala	Pro	Ala 105	Asn	Asp	Ile	Tyr	Asn 110	Glu	Arg
Glu	Leu 115	Leu	Asn	Ser	Met	Asn	Ile 120	Ser	Gln	Pro	Thr	Val 125	Val	Phe	Val
Ser	Lys 130	Lys	Gly	Leu	Gln	Lys 135	Ile	Leu	Asn	Val	Gln 140	Lys	Lys	Leu	Pro
Ile 145	Ile	Gln	Lys	Ile 150	Ile	Ile	Met	Asp	Ser	Lys 155	Thr	Asp	Tyr	Gln	Gly 160
Phe	Gln	Ser	Met	Tyr 165	Thr	Phe	Val	Thr	Ser 170	His	Leu	Pro	Pro	Gly 175	Phe
Asn	Glu	Tyr	Asp 180	Phe	Val	Pro	Glu	Ser 185	Phe	Asp	Arg	Asp	Lys 190	Thr	Ile
Ala	Leu 195	Ile	Met	Asn	Ser	Ser	Gly 200	Ser	Thr	Gly	Leu	Pro 205	Lys	Gly	Val
Ala 210	Leu	Pro	His	Arg	Thr	Ala 215	Cys	Val	Arg	Phe	Ser 220	His	Ala	Arg	Asp
Pro 225	Ile	Phe	Gly	Asn	Gln 230	Ile	Ile	Pro	Asp	Thr 235	Ala	Ile	Leu	Ser	Val 240
Val	Pro	Phe	His	His 245	Gly	Phe	Gly	Met	Phe 250	Thr	Thr	Leu	Gly	Tyr 255	Leu
Ile	Cys	Gly	Phe 260	Arg	Val	Val	Leu	Met 265	Tyr	Arg	Phe	Glu	Glu 270	Glu	Leu
Phe	Leu 275	Arg	Ser	Leu	Gln	Asp	Tyr 280	Lys	Ile	Gln	Ser	Ala 285	Leu	Leu	Val
Pro	Thr 290	Leu	Phe	Ser	Phe	Phe 295	Ala	Lys	Ser	Thr	Leu 300	Ile	Asp	Lys	Tyr
Asp 305	Leu	Ser	Asn	Leu	His 310	Glu	Ile	Ala	Ser	Gly 315	Gly	Ala	Pro	Leu	Ser 320
Lys	Glu	Val	Gly	Glu 325	Ala	Val	Ala	Lys	Arg 330	Phe	His	Leu	Pro	Gly 335	Ile
Arg	Gln	Gly	Tyr	Gly	Leu	Thr	Glu	Thr	Thr	Ser	Ala	Ile	Leu	Ile	Thr

340 345 350
 Pro Glu Gly Asp Asp Lys Pro Gly Ala Val Gly Lys Val Val Pro Phe
 355 360 365
 Phe Glu Ala Lys Val Val Asp Leu Asp Thr Gly Lys Thr Leu Gly Val
 370 375 380
 Asn Gln Arg Gly Glu Leu Cys Val Arg Gly Pro Met Ile Met Ser Gly
 385 390 395 400
 Tyr Val Asn Asn Pro Glu Ala Thr Asn Ala Leu Ile Asp Lys Asp Gly
 405 410 415
 Trp Leu His Ser Gly Asp Ile Ala Tyr Trp Asp Glu Asp Glu His Phe
 420 425 430
 Phe Ile Val Asp Arg Leu Lys Ser Leu Ile Lys Tyr Lys Gly Tyr Gln
 435 440 445
 Val Ala Pro Ala Glu Leu Glu Ser Ile Leu Leu Gln His Pro Asn Ile
 450 455 460
 Phe Asp Ala Gly Val Ala Gly Leu Pro Asp Asp Asp Ala Gly Glu Leu
 465 470 475 480
 Pro Ala Ala Val Val Val Leu Glu His Gly Lys Thr Met Thr Glu Lys
 485 490 495
 Glu Ile Val Asp Tyr Val Ala Ser Gln Val Thr Thr Ala Lys Lys Leu
 500 505 510
 Arg Gly Gly Val Val Phe Val Asp Glu Val Pro Lys Gly Leu Thr Gly
 515 520 525
 Lys Leu Asp Ala Arg Lys Ile Arg Glu Ile Leu Ile Lys Ala Lys Lys
 530 535 540
 Gly Gly Lys Ser Lys Leu
 545 550
 <210> 4
 <211> 286
 <212> PRT
 <213> Artificial
 <400> 4
 Met Ser Ile Gln His Phe Arg Val Ala Leu Ile Pro Phe Phe Ala Ala
 1 5 10 15
 Phe Cys Leu Pro Val Phe Ala His Pro Glu Thr Leu Val Lys Val Lys
 20 25 30
 Asp Ala Glu Asp Gln Leu Gly Ala Arg Val Gly Tyr Ile Glu Leu Asp
 35 40 45
 Leu Asn Ser Gly Lys Ile Leu Glu Ser Phe Arg Pro Glu Glu Arg Phe
 50 55 60
 Pro Met Met Ser Thr Phe Lys Val Leu Leu Cys Gly Ala Val Leu Ser
 65 70 75 80
 Arg Ile Asp Ala Gly Gln Glu Gln Leu Gly Arg Arg Ile His Tyr Ser
 85 90 95

05930585-030403

Gln	Asn	Asp	Leu 100	Val	Glu	Tyr	Ser	Pro 105	Val	Thr	Glu	Lys	His 110	Leu	Thr
Asp	Gly	Met 115	Thr	Val	Arg	Glu	Leu 120	Cys	Ser	Ala	Ala	Ile 125	Thr	Met	Ser
Asp	Asn 130	Thr	Ala	Ala	Asn	Leu 135	Leu	Leu	Thr	Thr	Ile 140	Gly	Gly	Pro	Lys
Glu 145	Leu	Thr	Ala	Phe	Leu 150	His	Asn	Met	Gly	Asp 155	His	Val	Thr	Arg	Leu 160
Asp	Arg	Trp	Glu	Pro 165	Glu	Leu	Asn	Glu	Ala 170	Ile	Pro	Asn	Asp	Glu 175	Arg
Asp	Thr	Thr	Met 180	Pro	Val	Ala	Met	Ala 185	Thr	Thr	Leu	Arg	Lys 190	Leu	Leu
Thr	Gly	Glu 195	Leu	Leu	Thr	Leu	Ala 200	Ser	Arg	Gln	Gln	Leu 205	Ile	Asp	Trp
Met	Glu 210	Ala	Asp	Lys	Val	Ala 215	Gly	Pro	Leu	Leu	Arg 220	Ser	Ala	Leu	Pro
Ala 225	Gly	Trp	Phe	Ile	Ala 230	Asp	Lys	Ser	Gly	Ala 235	Gly	Glu	Arg	Gly	Ser 240
Arg	Gly	Ile	Ile	Ala 245	Ala	Leu	Gly	Pro	Asp 250	Gly	Lys	Pro	Ser	Arg 255	Ile
Val	Val	Ile	Tyr 260	Thr	Thr	Gly	Ser	Gln 265	Ala	Thr	Met	Asp	Glu 270	Arg	Asn
Arg	Gln	Ile 275	Ala	Glu	Ile	Gly	Ala 280	Ser	Leu	Ile	Lys	His 285	Trp		

<110> LILIUS, Esa-Matti
VIRTA, Marko

<130> 2328-124

<151> 2000-06-07

<151> 1999-06-07

<160> 4

<170> PatentIn version 3.0

 $\langle 210 \rangle$ 1

<211> 5051

<212> DNA

<213> Artificial

 $\langle 220 \rangle$

<223> pGFP+Luc* plasmid

 $\langle 220 \rangle$

<221> promoter

<222> (95) . . (199)

<223> lac promoter

 $\langle 220 \rangle$

<221> gene

$$\langle 222 \rangle \quad (289) \dots (1005)$$

<223> Coding sequence for GFP

 $\langle 220 \rangle$

<221> gene

<222> (1044) .. (2693)

<223> coding sequence for firefly luciferase

 $\langle 220 \rangle$

<221> gene

$$\langle 222 \rangle \quad (3251) \dots (4108)$$

<223> coding sequence for beta-lactamase

<400> 1

agcgcccaat acgcaaaccg cctctccccg cgcgttggcc gattcattaa tgcagctggc 60

acgacagggtt tcccgactgg aaagcgggca gtgagcgcaa cgcaattaat gtgagtttagc 120

tcactcatta ggcaccccag gctttacact ttatgcttcc ggctcgatatg ttgtgtggaa 180

ttgtgagcgg ataacaattt cacacaggaa acagctatga ccatgattac gccaaqcttg 240

catgcctgca ggtcgactct agaggatccc cgggtaccgg tcgccaccat ggtgagcaag 300

ggcgaggagc tgttcaccgg ggtggtgcc atcctggtcg agctggacgg cgacgtaaac 360

ggccacaagt tcagcgtgtc cggcgagggc gagggcgatg ccacctacgg caagctgacc 420
 ctgaagttca tctgcaccac cggcaagctg cccgtgccct ggcccaccct cgtgaccacc 480
 ctgacctacg gcgtgcagtg cttcagccgc taccocgacc acatgaagca gcacgacttc 540
 ttcaagtccg ccatgcccga aggctacgtc caggagcgca ccatcttctt caaggacgac 600
 ggcaactaca agaccgcgc cgaggatgaag ttcgagggcg acacctggt gaaccgcac 660
 gagctgaagg gcatcgactt caaggaggac ggcaacatcc tggggcaca gctggagtac 720
 aactacaaca gccacaacgt ctatatcatg gccgacaagc agaagaacgg catcaagggtg 780
 aacttcaaga tccgccacaa catcgaggac ggagcggtgc agctcgccga cactaccag 840
 cagaacaccc ccatcgccga cggccccgtg ctgctgcccg acaaccacta cctgagcacc 900
 cagtcgccc tgagcaaaga cccaacgag aagcgcgac acatggctct gctggagttc 960
 gtgaccgcc cgggatcac tctcgcatg gacgagctgt acaagtaaag cggccgctct 1020
 agaactagt gatccccgt accatggaag acgcaaaaa cataaagaaa ggcccgccgc 1080
 cattctatcc gctagaggat ggaaccgctg gagagcaact gcataaggct atgaagagat 1140
 acgccctggt tcctggaaca attgctttta cagatgcaca tatcgagggtg aacatcacgt 1200
 acgcggaata cttcgaaatg tccgttcggt tggcagaagc tatgaaacga tatgggctga 1260
 atacaaatca cagaatcgtc gtagcagtg aaaactctct tcaattcttt atgccggtgt 1320
 tgggcgcgtt atttatcgga gttgcagttg cggccgcgaa cgacatttat aatgaacgtg 1380
 aattgctcaa cagtatgaac atttcgcagc ctaccgtagt gtttgtttcc aaaaaggggt 1440
 tgcaaaaaat tttgaacgtg caaaaaaat taccaataat ccagaaaatt attatcatgg 1500
 attctaaaac ggattaccag ggatttcagt cgatgtacac gttcgtcaca tctcatctac 1560
 ctcccggttt taatgaatac gattttgtac cagagtcctt tgatcgtgac aaaacaattg 1620
 cactgataat gaactcctct ggatctactg ggttacctaa ggggtgtggc cttccgcata 1680
 gaactgcctg cgtcagattc tcgcatgcc gagatcctat ttttggaat caaatcattc 1740
 cggatactgc gattttaagt gttgttccat tccatcacgg ttttggaatg ttactacac 1800
 tcggatatatt gatatgtgga tttcgagtcg tcttaatgta tagatttgaa gaagagctgt 1860
 ttttacgac ctttcaggat taaaaattc aaagtgcgtt gctagtacca accctatatt 1920
 cattcttcgc caaaagcact ctgattgaca aatacgattt atctaattta cacgaaattg 1980
 cttctggggg cgcacctctt tcgaaagaag tcggggaagc ggttgcaaaa cgcttccatc 2040
 ttccagggat acgacaagga tatgggctca ctgagactac atcagctatt ctgattacac 2100
 ccgaggggga tgataaaccg ggcgcggtcg gtaaagttgt tccatttttt gaagcgaagg 2160

ttgtggatct ggataaccggg aaaacgctgg gcgttaatca gagaggcgaa ttatgtgtca 2220
 gaggacctat gattatgtcc ggttatgtaa acaatccgga agcgaccaac gccttgattg 2280
 acaaggatgg atggctacat tctggagaca tagcttactg ggacgaagac gaacacttct 2340
 tcatagttga cgccttgaag tctttaatta aatacaaaagg ataccagggtg gcccccgctg 2400
 aattggagtc gatattgtta caacacccca acatcttcga cgcgggcggtg gcaggctctc 2460
 ccgacgatga cgcgggtgaa ctccccgccc ccgttggtgtg tttggagcac ggaaagacga 2520
 tgacggaaaa agagatcgtg gattacgtcg ccagtcaagt aacaaccgcc aaaaagttgc 2580
 gcggaggagt tgtgtttgtg gacgaagtac cgaaaaggtct taccgaaaa ctgcagcaa 2640
 gaaaaatcag agagatcctc ataaaggcca agaaggcgcg aaagtccaaa ttgtaaaatg 2700
 taactgtatt cagcgatgac gaaattctta gctattgtaa tactctaggg gctgcaggaa 2760
 ttcgatatca agcttatcga taccgtcgac ctgcaggggg ggccctttcg tctcgcgcgt 2820
 ttcggtgatg acggtgaaaa cctctgacac atgcagctcc cggagacggt cacagcttgt 2880
 ctgtaagcgg atgccgggag cagacaagcc cgtcagggcg cgtcagcggg tgttgccggg 2940
 tgtccgggct ggcttaacta tgcggcatca gagcagattg tactgagagt gcaccatattg 3000
 cgggtgtgaaa taccgcacag atgcgtaagg agaaaatacc gcatcaggcg gccttaaggg 3060
 cctcgtgata cgcctatttt tatagggtta tgtcatgata ataatggttt cttagacgtc 3120
 aggtggcact tttcggggaa atgtgcgcgg aaccttatt tgtttatttt tctaaatata 3180
 ttcaaataatg tatccgctca tgagacaata accctgataa atgcttcaat aatattgaaa 3240
 aaggaagagt atgagtattc aacatttccg tgtcgccctt attccctttt ttgcggcatt 3300
 ttgccttctt gtttttgctc acccagaaac gctggtgaaa gtaaaagatg ctgaagatca 3360
 gttgggtgca cgagtgggtt acatcgaact ggatctcaac agcggtaaga tccttgagag 3420
 ttttcgcccc gaagaacgtt ttccaatgat gagcactttt aaagttctgc tatgtggcgc 3480
 ggtattatcc cgtattgacg ccgggcaaga gcaactcggc cgcgcatac actattctca 3540
 gaatgacttg gttgagtact caccagtcac agaaaagcat cttacggatg gcatgacagt 3600
 aagagaatta tgcaagtgtg ccataacat gagtgataac actgcggcca acttacttct 3660
 gacaacgatc ggaggaccga aggagctaac cgcttttttg cacaacatgg gggatcatgt 3720
 aactcgcctt gatcgttggg aaccggagct gaatgaagcc ataccaaagc acgagcgtga 3780
 caccacgatg cctgtagcaa tggcaacaac gttgcgcaaa ctattaactg gcgaactact 3840
 tactctagct tcccggcaac aattaataga ctggatggag gcggataaag ttgcaggacc 3900
 acttctgcgc tcggcccttc cggctggctg gtttattgct gataaatctg gagccggtga 3960

gcgtgggtct cgcggtatca ttgcagcact ggggccagat ggtaagccct cccgtatcgt 4020
 agttatctac acgacgggga gtcaggcaac tatggatgaa cgaaatagac agatcgctga 4080
 gatagggtgcc tcaactgatta agcattggta actgtcagac caagtttact catatatact 4140
 ttagattgat ttaaaacttc atttttaatt taaaaggatc taggtgaaga tcctttttga 4200
 taatctcatg accaaaatcc cttaacgtga gttttcgttc cactgagcgt cagaccccgt 4260
 agaaaagatc aaaggatctt cttgagatcc tttttttctg cgcgtaatct gctgottgca 4320
 aacaaaaaaaa ccaccgctac cagcgggtgt ttgtttgccg gatcaagagc taccaactct 4380
 ttttcgaag gtaactggct tcagcagagc gcagatacca aatactgtcc ttctagtgt 4440
 gccgtagtta ggccaccact tcaagaactc tgtagcaccg cctacatacc tcgctctgct 4500
 aatcctgtta ccagtggctg ctgccagtgg cgataagtcg tgtcttaccg ggttggactc 4560
 aagacgatag ttaccggata aggcgcagcg gtcgggctga acgggggggtt cgtgcacaca 4620
 gccagcttg gagcgaacga cctacaccga actgagatac ctacagcgtg agctatgaga 4680
 aagcgccacg cttcccgaag ggagaaaggc ggacaggtat ccggtaaagc gcaggggtcg 4740
 aacaggagag cgcacgaggg agcttccagg gggaaacgcc tggatatctt atagtctgt 4800
 cgggtttcgc cacctctgac ttgagcgtcg atttttgtga tgctcgtcag gggggcggag 4860
 cctatggaaa aacgccagca acgcggcctt ttacgggtc ctggcctttt gctggccttt 4920
 tgctcacatg ttctttctctg cgttatcccc tgattctgtg gataaccgta ttaccgcctt 4980
 tgagtgaact gataccgctc gccgcagccg aacgaccgag cgcagcgagt cagtgagcga 5040
 ggaagcggaa g 5051

<210> 2
 <211> 239
 <212> PRT
 <213> Unknown

<220>
 <223> source of GFP unknown

<400> 2
 Met Val Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu
 1 5 10 15
 Val Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly
 20 25 30
 Glu Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile
 35 40 45
 Cys Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr
 50 55 60

Cys Ser Glu Asn Ser Leu Gln Phe Phe Met Pro Val Leu Gly Ala Leu
85 90 95

Phe	Ile	Gly	Val	Ala	Val	Ala	Pro	Ala	Asn	Asp	Ile	Tyr	Asn	Glu	Arg		
			100				105						110				
Glu	Leu	Leu	Asn	Ser	Met	Asn	Ile	Ser	Gln	Pro	Thr	Val	Val	Phe	Val		
			115				120						125				
Ser	Lys	Lys	Gly	Leu	Gln	Lys	Ile	Leu	Asn	Val	Gln	Lys	Lys	Leu	Pro		
			130				135						140				
Ile	Ile	Gln	Lys	Ile	Ile	Ile	Met	Asp	Ser	Lys	Thr	Asp	Tyr	Gln	Gly		
			145				150						155	160			
Phe	Gln	Ser	Met	Tyr	Thr	Phe	Val	Thr	Ser	His	Leu	Pro	Pro	Gly	Phe		
				165				170						175			
Asn	Glu	Tyr	Asp	Phe	Val	Pro	Glu	Ser	Phe	Asp	Arg	Asp	Lys	Thr	Ile		
			180				185						190				
Ala	Leu	Ile	Met	Asn	Ser	Ser	Gly	Ser	Thr	Gly	Leu	Pro	Lys	Gly	Val		
			195				200						205				
Ala	Leu	Pro	His	Arg	Thr	Ala	Cys	Val	Arg	Phe	Ser	His	Ala	Arg	Asp		
			210				215						220				
Pro	Ile	Phe	Gly	Asn	Gln	Ile	Ile	Pro	Asp	Thr	Ala	Ile	Leu	Ser	Val		
			225				230						235	240			
Val	Pro	Phe	His	His	Gly	Phe	Gly	Met	Phe	Thr	Thr	Leu	Gly	Tyr	Leu		
				245				250						255			
Ile	Cys	Gly	Phe	Arg	Val	Val	Leu	Met	Tyr	Arg	Phe	Glu	Glu	Glu	Leu		
			260				265						270				
Phe	Leu	Arg	Ser	Leu	Gln	Asp	Tyr	Lys	Ile	Gln	Ser	Ala	Leu	Leu	Val		
			275				280						285				
Pro	Thr	Leu	Phe	Ser	Phe	Phe	Ala	Lys	Ser	Thr	Leu	Ile	Asp	Lys	Tyr		
			290				295						300				
Asp	Leu	Ser	Asn	Leu	His	Glu	Ile	Ala	Ser	Gly	Gly	Ala	Pro	Leu	Ser		
			305				310						315	320			
Lys	Glu	Val	Gly	Glu	Ala	Val	Ala	Lys	Arg	Phe	His	Leu	Pro	Gly	Ile		
				325			330						335				
Arg	Gln	Gly	Tyr	Gly	Leu	Thr	Glu	Thr	Thr	Ser	Ala	Ile	Leu	Ile	Thr		
			340				345						350				
Pro	Glu	Gly	Asp	Asp	Lys	Pro	Gly	Ala	Val	Gly	Lys	Val	Val	Pro	Phe		
			355				360						365				
Phe	Glu	Ala	Lys	Val	Val	Asp	Leu	Asp	Thr	Gly	Lys	Thr	Leu	Gly	Val		
			370				375						380				
Asn	Gln	Arg	Gly	Glu	Leu	Cys	Val	Arg	Gly	Pro	Met	Ile	Met	Ser	Gly		
			385				390						395	400			
Tyr	Val	Asn	Asn	Pro	Glu	Ala	Thr	Asn	Ala	Leu	Ile	Asp	Lys	Asp	Gly		
				405			410						415				

Trp Leu His Ser Gly Asp Ile Ala Tyr Trp Asp Glu Asp Glu His Phe
420 425 430

Phe Ile Val Asp Arg Leu Lys Ser Leu Ile Lys Tyr Lys Gly Tyr Gln
435 440 445

Val Ala Pro Ala Glu Leu Glu Ser Ile Leu Leu Gln His Pro Asn Ile
450 455 460

Phe Asp Ala Gly Val Ala Gly Leu Pro Asp Asp Asp Ala Gly Glu Leu
465 470 475 480

Pro Ala Ala Val Val Val Leu Glu His Gly Lys Thr Met Thr Glu Lys
485 490 495

Glu Ile Val Asp Tyr Val Ala Ser Gln Val Thr Thr Ala Lys Lys Leu
500 505 510

Arg Gly Gly Val Val Phe Val Asp Glu Val Pro Lys Gly Leu Thr Gly
515 520 525

Lys Leu Asp Ala Arg Lys Ile Arg Glu Ile Leu Ile Lys Ala Lys Lys
530 535 540

Gly Gly Lys Ser Lys Leu
545 550

<210> 4

<211> 286

<212> PRT

<213> Unknown

<220>

<223> source of beta-lactamase unknown

<400> 4

Met Ser Ile Gln His Phe Arg Val Ala Leu Ile Pro Phe Phe Ala Ala
1 5 10 15

Phe Cys Leu Pro Val Phe Ala His Pro Glu Thr Leu Val Lys Val Lys
20 25 30

Asp Ala Glu Asp Gln Leu Gly Ala Arg Val Gly Tyr Ile Glu Leu Asp
35 40 45

Leu Asn Ser Gly Lys Ile Leu Glu Ser Phe Arg Pro Glu Glu Arg Phe
50 55 60

Pro Met Met Ser Thr Phe Lys Val Leu Leu Cys Gly Ala Val Leu Ser
65 70 75 80


Arg Ile Asp Ala Gly Gln Glu Gln Leu Gly Arg Arg Ile His Tyr Ser
85 90 95

Gln Asn Asp Leu Val Glu Tyr Ser Pro Val Thr Glu Lys His Leu Thr
100 105 110

Asp Gly Met Thr Val Arg Glu Leu Cys Ser Ala Ala Ile Thr Met Ser
115 120 125

Asp	Asn	Thr	Ala	Ala	Asn	Leu	Leu	Leu	Thr	Thr	Ile	Gly	Gly	Pro	Lys
130						135					140				
Glu	Leu	Thr	Ala	Phe	Leu	His	Asn	Met	Gly	Asp	His	Val	Thr	Arg	Leu
145					150					155					160
Asp	Arg	Trp	Glu	Pro	Glu	Leu	Asn	Glu	Ala	Ile	Pro	Asn	Asp	Glu	Arg
				165					170					175	
Asp	Thr	Thr	Met	Pro	Val	Ala	Met	Ala	Thr	Thr	Leu	Arg	Lys	Leu	Leu
			180					185					190		
Thr	Gly	Glu	Leu	Leu	Thr	Leu	Ala	Ser	Arg	Gln	Gln	Leu	Ile	Asp	Trp
	195						200					205			
Met	Glu	Ala	Asp	Lys	Val	Ala	Gly	Pro	Leu	Leu	Arg	Ser	Ala	Leu	Pro
	210					215					220				
Ala	Gly	Trp	Phe	Ile	Ala	Asp	Lys	Ser	Gly	Ala	Gly	Glu	Arg	Gly	Ser
225					230					235					240
Arg	Gly	Ile	Ile	Ala	Ala	Leu	Gly	Pro	Asp	Gly	Lys	Pro	Ser	Arg	Ile
				245					250					255	
Val	Val	Ile	Tyr	Thr	Thr	Gly	Ser	Gln	Ala	Thr	Met	Asp	Glu	Arg	Asn
			260					265					270		
Arg	Gln	Ile	Ala	Glu	Ile	Gly	Ala	Ser	Leu	Ile	Lys	His	Trp		
	275						280					285			

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



SCANNED, # 12

Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ **Scanned copy is best available.**

— There are only 5 drawings not 8.